Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1986-10-14
1989-06-06
Daus, Donald G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514230, 5142332, 544115, 544250, A61K 31505, A61K 3151, A61K 31525, C07D48704
Patent
active
048372390
ABSTRACT:
This invention is directed to a formulation of cardiotonic phosphodiesterase inhibitors with a water-soluble vitamin, comprising a lyophilization step performed on a solution of the complex in an aqueous/organic solvent system. The formulation results in a complex that has been found to have enhanced solubility (over the compound alone) in a parenterally or orally acceptable solvent, and the lyophilization process yields a product with superior stability permitting an extended shelf life.
REFERENCES:
patent: Re31617 (1984-06-01), Beverung, Jr. et al.
patent: 3128227 (1964-04-01), Kanegis et al.
patent: 3282778 (1966-11-01), Lobel
patent: 3932407 (1976-01-01), Beverung, Jr. et al.
patent: 3983119 (1976-09-01), Beverung, Jr. et al.
patent: 3983120 (1976-09-01), Beverung, Jr. et al.
patent: 3988340 (1976-10-01), Partyka et al.
patent: 4092410 (1978-05-01), Ogata et al.
patent: 4146718 (1979-03-01), Jenks et al.
patent: 4208521 (1980-06-01), Crenshaw et al.
patent: 4256748 (1981-03-01), Chodnekar et al.
patent: 4357330 (1982-11-01), Fleming, Jr. et al.
patent: 4390540 (1983-06-01), Chodnekar et al.
patent: 4432980 (1984-02-01), Fleming, Jr. et al.
patent: 4444777 (1984-04-01), Fleming, Jr. et al.
patent: 4490371 (1984-12-01), Jones et al.
patent: 4551459 (1985-11-01), Jones et al.
patent: 4568676 (1986-02-01), Smith
patent: 4591592 (1986-05-01), Chowhan
patent: 4593029 (1986-06-01), Venuti et al.
patent: 4596806 (1986-06-01), Ishikawa et al.
patent: 4610987 (1986-09-01), Ishikawa
patent: 4663320 (1987-05-01), Jones et al.
patent: 4670434 (1987-06-01), Venuti
patent: 4690925 (1987-09-01), Fried et al.
The Merck Index, 8th Ed., Stecher, Ed., Merck & Co., Rahway, N.J., (1968), p. 178.
Remington's Pharmaceutical Sciences, 16th Ed., Osol. Ed., Mac Co., (1980), pp. 1483-1484.
Chien, "Solubilization of Metronidazole by Water-Miscible Multi-Cosolvents and Water-Soluble Vitamins", J. of Parenteral Science and Technology, 38(1), 32,36 (1984).
Higuchi and Bolton, "The Solubility and Complexing Properties of Oxytetracycline and Tetracycline III", J. Amer. Pharmaceutical Assoc., 48(10), 557-564 (1959).
Truelove et al., "Solubility Enhancement of Some Developmental Anti-Cancer Mucleoside Analogs by Complex Action With Nicotinamide", Intern. J. of Pharmaceutics, 19, 17-25 (1984).
Fawzi et al., "Rationalization of Drug Complexation in Aqueous Solution by Use of Huckel Frontier Mulecular Orbitals", J. Pharm. Sci., 69, 104-106 (1980).
Derwent #37757A Corresponding to J7 8012568 to Takeda Chemical Ind. KK. (1978).
Derwent #37796A Corresponding to RD 169009 to Anonymous.
Derwent #83-767946 Corresponding to J5 8135822 to Chugai Pharmaceutical KK.
Derwent #86-216099 Corresponding to J6 1148123 to Daiichi Seiyaku KK.
Derwent #66850T to Alkaloida Vegyeszeti Gyar.
Derwent #32880C to Groning, R.
Derwent #80059D to Merck & Co. Inc.
Derwent #21320F to Takeda Chem Ind. Ltd.
Derwent #85-239345 to Hisamitsu.
Benjamin Eric J.
Visor Gary C.
Daus Donald G.
Lewis Brian
Moran Tom M.
Rivers Diana G.
Syntex (U.S.A.) Inc.
LandOfFree
Cardiotonic phosphodiesterase inhibitors complexed with water so does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cardiotonic phosphodiesterase inhibitors complexed with water so, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cardiotonic phosphodiesterase inhibitors complexed with water so will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-40818